Exploring High Growth Tech Stocks in the US December 2024

Overview: Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in RNA-targeted therapeutics and gene therapies for rare diseases, with a market cap of approximately $11.64 billion.

Operations: Sarepta Therapeutics focuses on discovering, developing, manufacturing, and delivering RNA-targeted therapeutics and gene therapies for rare diseases. The company generated approximately $1.64 billion in revenue from these activities.

Sarepta Therapeutics has transitioned into profitability this year, a significant turnaround highlighted by its third-quarter revenue surge to $467.17 million from $331.82 million year-over-year, reflecting a robust annual growth rate of 24.1%. This leap is underpinned by promising developments in gene therapy, notably with the EMERGENE trial for LGMD2E/R4, which could potentially enhance its market presence upon successful completion and FDA approval expected in 2025. The company’s strategic collaborations, like the recent one with Arrowhead Pharmaceuticals, further bolster its innovation trajectory and market positioning within biotech’s high-stakes arena.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Coherent Corp. is a company that develops, manufactures, and markets engineered materials and optoelectronic components for various global industries, with a market capitalization of approximately $15.43 billion.

Operations: Coherent Corp. generates revenue through three primary segments: Lasers ($1.41 billion), Materials ($1.51 billion), and Networking ($2.63 billion). The company’s operations cater to industrial, communications, electronics, and instrumentation markets globally.

Coherent is navigating a transformative phase with significant strides in both product innovation and strategic expansions. Recently, the company announced the Chameleon Discovery LX, enhancing its offerings in nonlinear microscopy—a field critical for advancing medical and scientific research. This launch aligns with Coherent’s commitment to maintaining a competitive edge through continuous R&D, evidenced by their substantial investment in this area. Additionally, Coherent has embraced strategic growth opportunities such as the $33 million investment under the CHIPS and Science Act to expand its manufacturing capabilities in Texas, which is anticipated to bolster its position within tech supply chains significantly. These moves not only demonstrate Coherent’s proactive approach in high-tech markets but also underscore its potential for growth amidst evolving industry demands.

• Click this link to deep-dive into the 238 companies within our US High Growth Tech and AI Stocks screener.

• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.

• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGS:ALNY NasdaqGS:SRPT and NYSE:COHR.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com